PMID- 33154775
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201107
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Dec
TI  - The clinical significance of apolipoprotein L1 in head and neck squamous cell 
      carcinoma.
PG  - 377
LID - 10.3892/ol.2020.12240 [doi]
LID - 377
AB  - Approximately 500,000 new head and neck squamous cell carcinoma (HNSCC) cases are 
      detected every year around the world, and its incidence ranks sixth among all 
      cancer types globally. Among these cases, oral squamous cell carcinoma (OSCC) and 
      laryngeal squamous cell carcinoma (LSCC) are HNSCC subtypes with high incidence 
      rates, especially in China. The present study examines the association between 
      the apolipoprotein L1 (APOL1) mRNA and protein expression and clinical parameters 
      in HNSCC. The two most common types (oral and larynx) of HNSCC were selected for 
      subgroup analyses. Immunohistochemistry (IHC) was used to detect APOL1 protein 
      expression levels in HNSCC clinical specimens. It was demonstrated that APOL1 
      protein expression in 221 cases of HNSCC was higher compared with that in normal 
      tissues. Consistent upregulation of APOL1 protein was also found in subgroups of 
      OSCC and LSCC. Through mining the ArrayExpress, The Cancer Genome Atlas and the 
      Gene Expression Omnibus databases, microarrays and RNA sequencing data for HNSCC 
      were retrieved, which were used to analyze APOL1 mRNA expression levels. The 
      results showed that APOL1 expression was higher in both OSCC and LSCC subtypes, 
      as well as in HNSCC, compared with that in non-cancerous squamous epithelium. The 
      summary receiver operating characteristic analysis showed that APOL1 had 
      potential as a diagnostic biomarker for HNSCC, OSCC and LSCC. Thus, upregulation 
      of APOL1 may contribute to the tumorigenesis of HNSCC.
CI  - Copyright: (c) Zhong et al.
FAU - Zhong, Feng
AU  - Zhong F
AD  - Department of Pathology, Hengxian People's Hospital, Nanning, Guangxi Zhuang 
      Autonomous Region 530300, P.R. China.
FAU - Lu, Hui-Ping
AU  - Lu HP
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Chen, Gang
AU  - Chen G
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Dang, Yi-Wu
AU  - Dang YW
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Zhang, Xiao-Guohui
AU  - Zhang XG
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Liang, Yao
AU  - Liang Y
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Li, Ming-Xuan
AU  - Li MX
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Li, Guo-Sheng
AU  - Li GS
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Chen, Xiao-Yi
AU  - Chen XY
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Yao, Yu-Xuan
AU  - Yao YX
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Qin, Yong-Ying
AU  - Qin YY
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Mo, Miao
AU  - Mo M
AD  - Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Zhang, Kai-Lang
AU  - Zhang KL
AD  - Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Ding, Hua
AU  - Ding H
AD  - Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Huang, Zhi-Guang
AU  - Huang ZG
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
FAU - Wei, Zhu-Xin
AU  - Wei ZX
AD  - Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20201022
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC7608033
OTO - NOTNLM
OT  - apolipoprotein L1
OT  - clinical significance
OT  - head and neck squamous cell carcinoma
OT  - subgroups
EDAT- 2020/11/07 06:00
MHDA- 2020/11/07 06:01
PMCR- 2020/10/22
CRDT- 2020/11/06 06:00
PHST- 2019/10/10 00:00 [received]
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/11/06 06:00 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2020/11/07 06:01 [medline]
PHST- 2020/10/22 00:00 [pmc-release]
AID - OL-0-0-12240 [pii]
AID - 10.3892/ol.2020.12240 [doi]
PST - ppublish
SO  - Oncol Lett. 2020 Dec;20(6):377. doi: 10.3892/ol.2020.12240. Epub 2020 Oct 22.